Prognostic and predictive clinical factors in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel.

about

Prognostic and predictive clinical factors in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel.

Item

http://www.wikidata.org/entity/Q53822455

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Prognostic and predictive clin ...... ncer treated with cabazitaxel.

@en

Prognostic and predictive clin ...... ncer treated with cabazitaxel.

@nl

type

Item

label

Prognostic and predictive clin ...... ncer treated with cabazitaxel.

@en

Prognostic and predictive clin ...... ncer treated with cabazitaxel.

@nl

prefLabel

Prognostic and predictive clin ...... ncer treated with cabazitaxel.

@en

Prognostic and predictive clin ...... ncer treated with cabazitaxel.

@nl

P1476

Prognostic and predictive clin ...... ncer treated with cabazitaxel.

@en

P2093

Carla Girolametto

http://www.w3.org/2001/XMLSchema#string

Daniel W Yokom

http://www.w3.org/2001/XMLSchema#string

Eric Winquist

http://www.w3.org/2001/XMLSchema#string

Fred Saad

http://www.w3.org/2001/XMLSchema#string

Helene Leonard

http://www.w3.org/2001/XMLSchema#string

Jean-Baptiste Lattouf

http://www.w3.org/2001/XMLSchema#string

John Stewart

http://www.w3.org/2001/XMLSchema#string

Nimira S Alimohamed

http://www.w3.org/2001/XMLSchema#string

Scott Berry

http://www.w3.org/2001/XMLSchema#string

Srikala S Sridhar

http://www.w3.org/2001/XMLSchema#string

P2860

Alpha emitter radium-223 and survival in metastatic prostate cancer

Increased survival with enzalutamide in prostate cancer after chemotherapy

Abiraterone and increased survival in metastatic prostate cancer

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.

Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer

Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer

Randomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-Naïve, Metastatic, Castration-Resistant Prostate Cancer.

P31

scholarly article

P356

10.5489/CUAJ.5108

http://www.w3.org/2001/XMLSchema#string

P577

2018-04-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29629866

http://www.w3.org/2001/XMLSchema#string

P932

6114156

http://www.w3.org/2001/XMLSchema#string